Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | SC |
incorrect route of vaccine administration; This non-serious case was reported by a physician via call center representative and described the occurrence of intramuscular formulation administered by other route in a adolescent patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis. On an unknown date, the patient received Tdap Vaccine (subcutaneous). On an unknown date, an unknown time after receiving Tdap Vaccine, the patient experienced intramuscular formulation administered by other route (Verbatim: incorrect route of vaccine administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date:11-JUL-2025 The reporter called to report a possible incorrect route of vaccine administration. The reporter stated that Boostrix was possibly administered sub-q, which led to intramuscular formulation administered by other route. The reporter also stated that what if needle was only inserted halfway for an adolescent, what if needle hit the bone. The reporter stated vaccine administered was Tdap but was unable to verify if the medication administered was Boostrix. The reporter declined to provide any information.